Loading…
Strengthen American Competitiveness Against Harmful Subsidies Act of 2025
Legislative Progress
Introduced
March 27, 2025
Latest Action
March 27, 2025
Primary Sponsor
Margaret Wood HassanDemocratic(NH)
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,674 other S bills in the 119th — cohort avg 32d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (1)
2026 · second_quarter · Health Issues
GHAI Overdose Initiative (under healthcare issue code): Legislation: FY 27 Appropriations bills Modernizing Opioid Treatment Access Act S. 1165/H. R. 2586, Reentry Act H.R. 5629 Issues: Medicaid prior authorization requirements Access to medications for opioid use disorder Overdose prevention Racial disparities in overdose deaths Financing (grants) for behavioral health care services and programs FY 2027 National Drug Control Policy Medicaid funding and federal guidance related to harm reduction Agencies Visited: Centers for Disease Control and Prevention US House of Representatives US Senate Substance Abuse and Mental Health Services Administration
Client expense: $300,000 · Firm income: Not reported
Read twice and referred to the Committee on Finance.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
2026 · second_quarter · Health Issues
GHAI Overdose Initiative (under healthcare issue code): Legislation: FY 27 Appropriations bills Modernizing Opioid Treatment Access Act S. 1165/H. R. 2586, Reentry Act H.R. 5629 Issues: Medicaid prior authorization requirements Access to medications for opioid use disorder Overdose prevention Racial disparities in overdose deaths Financing (grants) for behavioral health care services and programs FY 2027 National Drug Control Policy Medicaid funding and federal guidance related to harm reduction Agencies Visited: Centers for Disease Control and Prevention US House of Representatives US Senate Substance Abuse and Mental Health Services Administration
Client expense: $290,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
2026 · second_quarter · Health Issues
GHAI Overdose Initiative (under healthcare issue code): Legislation: FY 27 Appropriations bills Modernizing Opioid Treatment Access Act S. 1165/H. R. 2586, Reentry Act H.R. 5629 Issues: Medicaid prior authorization requirements Access to medications for opioid use disorder Overdose prevention Racial disparities in overdose deaths Financing (grants) for behavioral health care services and programs FY 2027 National Drug Control Policy Medicaid funding and federal guidance related to harm reduction Agencies Visited: Centers for Disease Control and Prevention US House of Representatives US Senate Substance Abuse and Mental Health Services Administration
Client expense: $284,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
2026 · first_quarter · Health Issues
GHAI Overdose Initiative (under healthcare issue code): Legislation: FY 26 Appropriations bills Modernizing Opioid Treatment Access Act PEER Support Act H.R. 5420 - Workplace Overdose Reversal Kits to Save Lives Act S.3522 - No Red Tape For Addiction Treatment Act S. 1165/H. R. 2586, Reentry Act S. 1720/H.R. 1510, Due Process Continuity of Care Act S. 2697, Due Process Continuity of Care Act SUPPORT for Patients and Communities Reauthorization Act Issues: Medicaid prior authorization requirements Access to medications for opioid use disorder Overdose prevention Racial disparities in overdose deaths Financing (grants) for behavioral health care services and programs Agencies Visited: Centers for Disease Control and Prevention US House of Representatives US Senate
Client expense: $430,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE
2025 · fourth_quarter · Health Issues
GHAI Overdose Initiative (under healthcare issue code): Legislation: FY 26 Appropriations bills Modernizing Opioid Treatment Access Act PEER Support Act H.R. 5420 - Workplace Overdose Reversal Kits to Save Lives Act S.3522 - No Red Tape For Addiction Treatment Act S. 1165/H. R. 2586, Reentry Act S. 1720/H.R. 1510, Due Process Continuity of Care Act S. 2697, Due Process Continuity of Care Act SUPPORT for Patients and Communities Reauthorization Act Issues: Medicaid prior authorization requirements Access to medications for opioid use disorder Overdose prevention Racial disparities in overdose deaths Agencies Visited: Centers for Disease Control and Prevention US House of Representatives US Senate
Client expense: $980,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE
2025 · third_quarter · Health Issues
GHAI Overdose Initiative (under healthcare issue code): Legislation: FY 26 Appropriations bills Modernizing Opioid Treatment Access Act PEER Support Act S. 1165/H. R. 2586, Reentry Act S. 1720/H.R. 1510, Due Process Continuity of Care Act S. 2697, Due Process Continuity of Care Act SUPPORT for Patients and Communities Reauthorization Act Issues: Medicaid prior authorization requirements Access to medications for opioid use disorder Overdose prevention Racial disparities in overdose deaths Agencies Visited: Centers for Disease Control and Prevention US House of Representatives US Senate
Client expense: $480,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE
2025 · second_quarter · Health Issues
GHAI Overdose Initiative (under healthcare issue code): Legislation: H.R.1510/S. 971 - Due Process Continuity of Care Act S. 1165/ H. R. 2586 - Reentry Act HR 2483- The SUPPORT for Patients and Communities Reauthorization Act of 2025 FY 26 Labor Health and Human Services, Education, and Related Agencies Appropriations Act Issues: Medicaid coverage for individuals with substance use disorder Medicaid reform in jails/prisons Federal grant funding to support substance use prevention, treatment, and recovery services Methadone access Agencies Visited: US Senate US House of Representatives
Client expense: $1,780,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · first_quarter · Health Issues
GHAI Overdose Initiative (under healthcare issue code): Legislation: H.R.1510/S. 971 - Due Process Continuity of Care Act S. 1165/ H. R. 2586 - Reentry Act Issues: Medicare coverage for seniors with substance use disorder Medicaid reform in jails/prisons Methadone access ONDCP Funding Agencies Visited: US Senate US House of Representatives SAMHSA
Client expense: $380,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)